AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8978228 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotic illness diagnosis
Number of subjects: 750
Study 8978228 — intervention group
Group type: EXPERIMENTAL
Intervention: Personality disorder diagnosis
Number of subjects: 750
Study 8978228 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosis diagnosis
Number of subjects: 750
Study 8978228 — intervention group
Group type: EXPERIMENTAL
Intervention: Other and uncertain diagnoses
Number of subjects: 750
Study 8978228 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment need
Number of subjects: 750
Study 8978228 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer to NHS bed
Number of subjects: 750
Study 8978228 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment by prison health care services
Number of subjects: 750
Study 8978228 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing for substance misuse
Number of subjects: 750
Study 8978228 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic community placement
Number of subjects: 750
Study 1321859 — intervention group
Group type: EXPERIMENTAL
Intervention: Oka strain live attenuated varicella-zoster virus (VZV) vaccine, administered subcutaneously at doses varying from 1100 to 12,000 pfu, with one cohort receiving 3000 pfu and a 3000 pfu booster 3 months later.
Number of subjects: 202
Study 1321859 — intervention group
Group type: EXPERIMENTAL
Intervention: Oka strain live attenuated varicella-zoster virus (VZV) vaccine
Number of subjects: 202
Study 6376042 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU Calcitonin‐Sandoz
Number of subjects: 20
Study 29189266 — intervention group
Group type: COMPARATOR
Intervention: Air Loss of Resistance (ALOR) technique
Number of subjects: 376
Study 29189266 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline Loss of Resistance (SLOR) technique
Number of subjects: 376
Study 27048152 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment (MMT)
Number of subjects: 183
Study 24118368 — intervention group
Group type: COMPARATOR
Intervention: One-piece titanium implants
Number of subjects: 24
Study 24118368 — intervention group
Group type: EXPERIMENTAL
Intervention: One-piece zirconia implants
Number of subjects: 24
Study 22632588 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar SNAG (sustained natural apophyseal glide)
Number of subjects: 45
Study 22632588 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham technique (simulated SNAG without applying force)
Number of subjects: 45
Study 22632588 — intervention group
Group type: COMPARATOR
Intervention: Control group (static sitting position)
Number of subjects: 45
Study 20439247 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal tolerance test (high-glucose load meal)
Number of subjects: 15
Study 20439247 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 15
Study 20439247 — intervention group
Group type: EXPERIMENTAL
Intervention: Body composition measurement
Number of subjects: 15
Study 17363746 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 5145
Study 17363746 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 5145
Study 16325139 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed message intervention
Number of subjects: 1104
Study 16325139 — intervention group
Group type: COMPARATOR
Intervention: Usual communication (control)
Number of subjects: 1104
Study 12075219 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) 0.4 mg/mL applied for 4 minutes
Number of subjects: 55
Study 12075219 — intervention group
Group type: COMPARATOR
Intervention: Saline control applied for 4 minutes
Number of subjects: 55
Study 9457334 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex ultrasound
Number of subjects: 112
Study 9457334 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid crystal contact thermography (LCCT)
Number of subjects: 112
Study 9457334 — intervention group
Group type: COMPARATOR
Intervention: Phlebography (control)
Number of subjects: 112
Study 8545862 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplantation
Number of subjects: 6400
Study 8545862 — intervention group
Group type: COMPARATOR
Intervention: Dialysis
Number of subjects: 6400
Study 1477004 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 10
Study 1477004 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclofenil
Number of subjects: 10
Study 1477004 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 10
Study 6389378 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bumetanide
Number of subjects: 44
Study 6389378 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bumetanide
Number of subjects: 44
Study 6389378 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 44
Study 31349792 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day ECG monitoring patch (Zio® Patch, iRhythm Technologies)
Number of subjects: 116
Study 31349792 — intervention group
Group type: COMPARATOR
Intervention: Short-duration Holter monitoring
Number of subjects: 116
Study 28525614 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg lidocaine (group RL40)
Number of subjects: 1095
Study 28525614 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mg/kg lidocaine (group LL1.2)
Number of subjects: 1095
Study 28525614 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg lidocaine
Number of subjects: 1095
Study 28525614 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (group PR)
Number of subjects: 1095
Study 27516476 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-only ART (lopinavir/ritonavir/saquinavir) for 24 weeks
Number of subjects: 48
Study 27128611 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 25 mg
Number of subjects: 0
Study 27128611 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 200 mg
Number of subjects: 0
Study 27128611 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 0
Study 27128611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21922171 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg)
Number of subjects: 25
Study 21922171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 20621270 — intervention group
Group type: EXPERIMENTAL
Intervention: Persica extract chewing gum with scaling (S+/P+)
Number of subjects: 72
Study 20621270 — intervention group
Group type: COMPARATOR
Intervention: Placebo chewing gum with scaling (S+/P-)
Number of subjects: 72
Study 20621270 — intervention group
Group type: EXPERIMENTAL
Intervention: Persica extract chewing gum without scaling (S-/P+)
Number of subjects: 72
Study 20621270 — intervention group
Group type: COMPARATOR
Intervention: Placebo chewing gum without scaling (S-/P-)
Number of subjects: 72
Study 17394474 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercises
Number of subjects: 53
Study 17394474 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercises
Number of subjects: 53
Study 16386524 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis (PP) and intravenous immunoglobulin (IVIG)
Number of subjects: 7
Study 12048292 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) plus placebo (n=39)
Number of subjects: 113
Study 12048292 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) plus folic acid (n=35)
Number of subjects: 113
Study 12048292 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) plus folinic acid (n=39)
Number of subjects: 113
Study 10361625 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone-misoprostol medical abortion
Number of subjects: 1373
Study 10361625 — intervention group
Group type: COMPARATOR
Intervention: Surgical abortion
Number of subjects: 1373
Study 7608861 — intervention group
Group type: EXPERIMENTAL
Intervention: Accurate attitude reporting
Number of subjects: 0
Study 7608861 — intervention group
Group type: EXPERIMENTAL
Intervention: Misreported attitudes (neutral or negative)
Number of subjects: 0
Study 7608861 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitude reports and LPPs to negative, neutral, and positive stimuli preceded by negative stimuli
Number of subjects: 0
Study 2793391 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioversol 320
Number of subjects: 24
Study 2793391 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 24
Study 337982 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate, 200 mg, intramuscularly weekly
Number of subjects: 50
Study 337982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30797761 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 30797761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29096835 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoprotein apheresis (LA) treatment, weekly for 2 years
Number of subjects: 150
Study 29096835 — intervention group
Group type: COMPARATOR
Intervention: Maximum tolerated lipid lowering therapy (control group)
Number of subjects: 150
Study 25862777 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive RRT
Number of subjects: 817
Study 25862777 — intervention group
Group type: COMPARATOR
Intervention: Less-intensive RRT
Number of subjects: 817
Study 25862777 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive RRT with high day 1 biomarkers (IL-6, macrophage migration inhibitory factor, TNFR-I)
Number of subjects: 817
Study 25862777 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive RRT with low day 1 biomarkers
Number of subjects: 817
Study 25862777 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated biomarkers on day 8 among 476 participants
Number of subjects: 817
Study 23324699 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program providing additional knowledge and demonstrating 'how-to' apply recommendations at the workstation
Number of subjects: 0
Study 23324699 — intervention group
Group type: COMPARATOR
Intervention: Pre-existing office ergonomic checklist training
Number of subjects: 0
Study 21498149 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine (FTC) dosed once daily
Number of subjects: 1363
Study 21498149 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine (3TC) dosed twice daily
Number of subjects: 1363
Study 21498149 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine (FTC)
Number of subjects: 1363
Study 21498149 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine (3TC)
Number of subjects: 1363
Study 19249153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hormonal therapy (IHT) with cyproterone acetate (CPA) 200mg for 2 weeks and then monthly depot injections of a luteinising hormone-releasing hormone (LHRH) analogue plus 200mg of CPA daily during induction. Patients randomised to the intermittent arm ceased treatment.
Number of subjects: 766
Study 19249153 — intervention group
Group type: COMPARATOR
Intervention: Continuous therapy with 200mg of CPA daily plus an LHRH analogue.
Number of subjects: 766
Study 19249153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hormonal therapy (IHT)
Number of subjects: 766
Study 19249153 — intervention group
Group type: COMPARATOR
Intervention: Continuous therapy
Number of subjects: 766
Study 16915302 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin care (STSC)
Number of subjects: 1704
Study 15521689 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorical perception near vertical orientation
Number of subjects: 0
Study 15521689 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous perception near horizontal orientation
Number of subjects: 0
Study 15521689 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorting oriented line stimuli into categories
Number of subjects: 0
Study 11508043 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Number of subjects: 30
Study 11508043 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 30
Study 9383182 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (50-250 mg/day)
Number of subjects: 18
Study 9383182 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (3-20 mg/day)
Number of subjects: 18
Study 8304581 — intervention group
Group type: EXPERIMENTAL
Intervention: Wobenzym (proteolytic, glycolytic, and lipolytic enzymes and rutoside)
Number of subjects: 80
Study 8304581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 3684175 — intervention group
Group type: EXPERIMENTAL
Intervention: aminoglutethimide 1000 mg/day + hydrocortisone 20 mg/day
Number of subjects: 29
Study 3684175 — intervention group
Group type: EXPERIMENTAL
Intervention: aminoglutethimide 250 mg/day
Number of subjects: 29
Study 3684175 — intervention group
Group type: EXPERIMENTAL
Intervention: aminoglutethimide (both dosages)
Number of subjects: 29
Study 29556903 — intervention group
Group type: EXPERIMENTAL
Intervention: e-alert group
Number of subjects: 875
Study 29556903 — intervention group
Group type: COMPARATOR
Intervention: non-e-alert group
Number of subjects: 875
Study 27011002 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) - once-daily (long-acting) for 4 weeks
Number of subjects: 163
Study 27011002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 27011002 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) - highest dose
Number of subjects: 163
Study 23959630 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate (SrRan) 2 g per day
Number of subjects: 387
Study 23959630 — intervention group
Group type: COMPARATOR
Intervention: Alendronate (ALN) 70 mg per week
Number of subjects: 387
Study 23876458 — intervention group
Group type: EXPERIMENTAL
Intervention: Boceprevir
Number of subjects: 1020
Study 23876458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1020
Study 20226890 — intervention group
Group type: EXPERIMENTAL
Intervention: Ag85B-ESAT-6 vaccine with IC31 adjuvant
Number of subjects: 0
Study 20226890 — intervention group
Group type: EXPERIMENTAL
Intervention: Ag85B-ESAT-6 vaccine without IC31 adjuvant
Number of subjects: 0
Study 20226890 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 18344850 — intervention group
Group type: EXPERIMENTAL
Intervention: Eperisone hydrochloride (EMPP) for 4 weeks
Number of subjects: 74
Study 18344850 — intervention group
Group type: EXPERIMENTAL
Intervention: McKenzie therapy
Number of subjects: 74
Study 18344850 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy only (control)
Number of subjects: 74
Study 15809409 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 104
Study 15809409 — intervention group
Group type: COMPARATOR
Intervention: Continuation medication
Number of subjects: 104
Study 12584366 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 6083
Study 12584366 — intervention group
Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 6083
Study 12584366 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors (among male subjects)
Number of subjects: 6083
Study 12584366 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors (among female subjects)
Number of subjects: 6083
Study 10321419 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone 2000 mg/d
Number of subjects: 12
Study 10321419 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac 400 mg/d
Number of subjects: 12
Study 10321419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8723378 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release L-DOPA/carbidopa (100/25 mg)
Number of subjects: 5
Study 1862734 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 123
Study 1862734 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 123
Study 1862734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 6412390 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium heparin 5000 IU subcutaneously every 12 hours for 7 days
Number of subjects: 21
Study 6412390 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-synthetic heparin analogue (SSHA) 75 mg subcutaneously every 12 hours for 7 days
Number of subjects: 21
Study 31957555 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplement (2000 IU/day)
Number of subjects: 46
Study 31957555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 31515191 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP flap
Number of subjects: 50
Study 31515191 — intervention group
Group type: COMPARATOR
Intervention: LD flap
Number of subjects: 50
Study 27910150 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-2952 20 mg
Number of subjects: 200
Study 27910150 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-2952 60 mg
Number of subjects: 200
Study 27910150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 26625090 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenging parenting behaviour by fathers
Number of subjects: 164
Study 26625090 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenging parenting behaviour by mothers
Number of subjects: 164
Study 26625090 — intervention group
Group type: COMPARATOR
Intervention: Children with anxiety disorder (n=74)
Number of subjects: 164
Study 22933501 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive patients undergoing clean surgery
Number of subjects: 609
Study 22933501 — intervention group
Group type: COMPARATOR
Intervention: HIV-negative patients undergoing clean surgery
Number of subjects: 609
Study 22933501 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive patients with open fractures or contamination
Number of subjects: 609
Study 22933501 — intervention group
Group type: COMPARATOR
Intervention: HIV-negative patients with open fractures or contamination
Number of subjects: 609
Study 22933501 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive patients
Number of subjects: 609
Study 22933501 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive patients with previous contamination
Number of subjects: 609
Study 19243306 — intervention group
Group type: EXPERIMENTAL
Intervention: OXN PR (60-80 mg/day)
Number of subjects: 265
Study 19243306 — intervention group
Group type: COMPARATOR
Intervention: OXY PR alone (60-80 mg/day)
Number of subjects: 265
Study 18724187 — intervention group
Group type: EXPERIMENTAL
Intervention: Eban Health Promotion Intervention
Number of subjects: 0
Study 16331792 — intervention group
Group type: EXPERIMENTAL
Intervention: Synovial tissue analysis in treatment strategies for rheumatoid arthritis
Number of subjects: 0
Study 16331792 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 11853235 — intervention group
Group type: EXPERIMENTAL
Intervention: Super‐EBA (EBA) root-end fillings
Number of subjects: 24
Study 11853235 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro Root MTA (MTA) root-end fillings
Number of subjects: 24
Study 11853235 — intervention group
Group type: COMPARATOR
Intervention: Microcracking
Number of subjects: 24
Study 10443984 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride (0 and 125 microg/kg)
Number of subjects: 78
Study 10443984 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosyntropin (0, 0.25 microg, and 250 microg)
Number of subjects: 78
Study 10443984 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol monitoring over a 24‐hr interval
Number of subjects: 78
Study 7778636 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (50 microgram tablets every 3 hours for a maximum of six doses)
Number of subjects: 135
Study 7778636 — intervention group
Group type: COMPARATOR
Intervention: Intracervical dinoprostone (0.5 mg every 6 hours for a maximum of three doses)
Number of subjects: 135
Study 7778636 — intervention group
Group type: COMPARATOR
Intervention: Intracervical dinoprostone
Number of subjects: 135
Study 7778636 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 135
Study 2138488 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia using a 29-gauge spinal needle
Number of subjects: 100
Study 2138488 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 100
Study 7189333 — intervention group
Group type: COMPARATOR
Intervention: Morphine sulfate (2 mg/kg)
Number of subjects: 40
Study 7189333 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (21 mg/kg)
Number of subjects: 40
Study 30528459 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraneural injection (1ml solution)
Number of subjects: 60
Study 30528459 — intervention group
Group type: COMPARATOR
Intervention: Perineural injection (1ml solution)
Number of subjects: 60
Study 28938956 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg followed by 90 mg twice daily
Number of subjects: 140
Study 28938956 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 300 mg followed by 75 mg daily
Number of subjects: 140
Study 24117412 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-fluence photodynamic therapy (RDPDT) with Verteporfin (25 J/cm²) followed by intravitreal bevacizumab 1.25 mg
Number of subjects: 95
Study 24117412 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal bevacizumab alone
Number of subjects: 95
Study 24117412 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-fluence photodynamic therapy (RDPDT) with Verteporfin followed by intravitreal bevacizumab
Number of subjects: 95
Study 22324456 — intervention group
Group type: EXPERIMENTAL
Intervention: BCP (Straumann BoneCeramic)
Number of subjects: 30
Study 22324456 — intervention group
Group type: EXPERIMENTAL
Intervention: ABB (Geistlich Bio‐Oss)
Number of subjects: 30
Study 22324456 — intervention group
Group type: EXPERIMENTAL
Intervention: AB (Autologous Bone)
Number of subjects: 30
Study 22324456 — intervention group
Group type: EXPERIMENTAL
Intervention: MCBA (Zimmer Puros)
Number of subjects: 30
Study 21495900 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g E. officinalis powder per day
Number of subjects: 0